Protocol Ledger

NCT06329401 · Phase II · ACTIVE NOT RECRUITING

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Interventional Phase II clinical trial protocol NCT06329401 sponsored by Avalyn Pharma in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-03 Enrollment: 398 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06329401
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)398 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06329401
Protocol FieldVerified Registry Value
NCT IdentifierNCT06329401
Consolidated Lead SponsorAvalyn Pharma
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment398 participants (ACTUAL)
Registered Start Date2024-04-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI